Fabi.ai

Fabi.ai, founded in the early 2020s, emerged as a specialized AI-driven platform focused on enhancing aesthetic medicine through advanced data analytics and personalized treatment recommendations. The company initially gained traction by collaborating with leading dermatologists and aesthetic practitioners to develop tools that streamline patient care and improve treatment outcomes. Fabi.ai’s product portfolio includes AI-powered diagnostic tools and treatment planning software designed to assist healthcare providers in delivering precise and effective aesthetic interventions.

The company has positioned itself as a key player in the regenerative aesthetics market, leveraging its proprietary algorithms to analyze skin health and recommend tailored therapies. Fabi.ai’s customer base primarily consists of dermatology clinics, aesthetic medicine practitioners, and medical spas seeking to integrate technology into their practice. Financially, Fabi.ai has secured significant funding rounds, including a $170 million Series B in 2024, valuing the company at $1.2 billion.

This funding has fueled its expansion into international markets, particularly in Europe and Asia, where demand for advanced aesthetic solutions is growing rapidly. What makes Fabi.ai particularly interesting now is its focus on addressing the aesthetic needs of patients undergoing medication-driven weight loss, a rapidly expanding demographic. The company’s recent innovations include Ultherapy PRIME®, a next-generation non-invasive skin lifting device, and AI-driven tools for managing facial changes post-weight loss. Fabi.ai continues to collaborate with industry experts to refine its offerings and maintain its leadership in the aesthetics technology space.